Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

780.67 +1.39 (+0.18%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa. 
Via Benzinga
Topics Lawsuit
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Why Viking Therapeutics Stock Popped Today
2025 is the year we learn whether Viking Therapeutics stock will be a winner. 
Via The Motley Fool
Eli Lilly Stock Gets A Double Downgrade And Price Target Cut By HSBC Over Valuation, Competition Concerns
HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss... 
Via Stocktwits
Topics Lawsuit
IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval
The company says a new process will improve its output by 20%, benefitting revenue and earnings later this year. 
Via Investor's Business Daily
3 Volatile Stocks with Questionable Fundamentals
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
This Eli Lilly Analyst Turns Bearish; Here Are Top 4 Downgrades For Monday
Via Benzinga
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its... 
Via Stocktwits
Topics Intellectual Property
Cramer's Warning: Tariff Chaos Could Derail Tech Earnings Frenzy This Week
Jim Cramer is preparing investors for another action-packed week on Wall Street, packed with earnings reports from major tech players and key economic updates. 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Novo Nordisk Stock Dropped Today
Ignore the noise. Novo Nordisk stock is a bargain. 
Via The Motley Fool
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard. 
Via MarketBeat
The Best Stock to Buy With Less Than $60 in the Market Sell-Off
Via The Motley Fool
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement
Groundbreaking ALS Therapy Shows Remarkable Survival Benefits as NeuroSense Continues to Advance Toward Potential Partnership with Pharma Giant (NASDAQ: NRSN)* 
Via News Direct
3 Profitable Stocks Walking a Fine Line
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales. 
Via Investor's Business Daily
Topics ETFs
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Via The Motley Fool
Pony.ai Targets Robotaxi Mass Production From Mid-2025: But Retail Sentiment Falters
The company unveiled three seventh-generation robotaxi models developed through its partnerships with Toyota, BAIC, and GAC at the Shanghai International Automobile Industry Exhibition on Wednesday. 
Via Stocktwits
Topics Artificial Intelligence Lawsuit
Eli Lilly Sues Four Telehealth Companies Selling Copies Of Its Weight-Loss Drug, Says Report: But Retail Stays Optimistic
According to a CNBC report, the company filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Med on Wednesday, alleging that they deceived consumers about “untested, unapproved... 
Via Stocktwits
Topics Lawsuit
Boston Scientific Stock Jets 8% Higher On Solid Quarterly Beat, Hiked Guidance
Boston Scientific stock jumped Wednesday after the medtech company beat first-quarter expectations and hiked its sales view. 
Via Investor's Business Daily
Topics Retirement
Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives
Via Benzinga
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Topics World Trade
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.